Coya Therapeutics, Inc. (COYA)
NASDAQ: COYA · Real-Time Price · USD
6.72
+0.65 (10.71%)
At close: Jul 24, 2025, 4:00 PM
6.50
-0.22 (-3.27%)
After-hours: Jul 24, 2025, 6:24 PM EDT

Company Description

Coya Therapeutics, Inc., a clinical-stage biotechnology company, develops proprietary therapies to enhance the function of regulatory T cells (Tregs).

The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.

It develops COYA 302, a biologic combination for subcutaneous administration intended to enhance Treg function while depleting T effector function and activated macrophages in Phase 2 trial for use in the treatment of amyotrophic lateral sclerosis, as well as frontotemporal dementia, Alzheimer’s disease (AD), and Parkinson’s disease.

In addition, the company’s pre-clinical product candidates include COYA 301, a low-dose interleukin 2 product candidate to treat AD; COYA 303, an investigational biologic combination of COYA 301 and a glucagon-like-peptide-1 receptor agonist for the treatment of inflammatory diseases; COYA 201, an antigen directed Treg-derived exosome product candidate to treat neurodegenerative, autoimmune, and metabolic diseases; COYA 206, an antigen directed Treg-derived exosome product candidate; and COYA 101.

It has a collaboration with Dr. Reddy's Laboratories SA for the development and commercialization of COYA 302, an investigational combination therapy for treatment of amyotrophic lateral sclerosis.

Coya Therapeutics, Inc. was founded in 2020 and is headquartered in Houston, Texas.

Coya Therapeutics, Inc.
Coya Therapeutics logo
CountryUnited States
Founded2020
IPO DateDec 29, 2022
IndustryBiotechnology
SectorHealthcare
Employees8
CEOArun Swaminathan

Contact Details

Address:
5850 San Felipe St., Suite 500
Houston, Texas 77057
United States
Phone800 587 8170
Websitecoyatherapeutics.com

Stock Details

Ticker SymbolCOYA
ExchangeNASDAQ
Stock TypeCommon Stock
Fiscal YearJanuary - December
Reporting CurrencyUSD
IPO Price$5.00
CIK Code0001835022
ISIN NumberUS22407B1089
SIC Code2834

Key Executives

NamePosition
Dr. Arun Swaminathan Ph.D.Chief Executive Officer and Director
Dr. Howard H. Berman Ph.D.Executive Chair
Dr. Fred Grossman D.O., FAPAPresident and Chief Medical Officer
David S. SnyderChief Financial Officer and Chief Operating Officer
Dr. Michelle Frazier Ph.D.Senior Vice President of Regulatory Affairs
Aaron Thome Ph.D.Head of Neuroinflammation Platform
Karen King M.S.Senior Vice President of Program Management and Clinical Operations

Latest SEC Filings

DateTypeTitle
Jul 1, 20258-KCurrent Report
Jun 26, 20258-KCurrent Report
May 16, 2025ARSFiling
May 16, 2025DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) material
May 16, 2025DEF 14AOther definitive proxy statements
May 13, 202510-QQuarterly Report
May 13, 20258-KCurrent Report
Apr 28, 202510-K/A[Amend] Annual report
Mar 18, 202510-KAnnual Report
Mar 18, 20258-KCurrent Report